GlassScriptPhysician profile
Laura E Glass
NPI 1124674031
$1,329.69
in general payments reported to CMS, 2019-2025
11 companies · $40.43 in 2025
The $40.43 reported for 2025 was less than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $293 · 2022: $357 · 2023: $301 · 2024: $338 · 2025: $40.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $679.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $664.43 | 2021-2024 | Nuzyra |
| Organogenesis INC. | $190.66 | 2021-2023 | Puraply |
| Smith+Nephew, INC. | $187.13 | 2022-2025 | Collagenase Santyl, Regranex |
| Cumberland Pharmaceuticals, INC. | $71.37 | 2021-2022 | |
| Kerecis Limited | $50.64 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Convatec INC. | $38.98 | 2021-2022 | |
| Urgo Medical North America, LLC | $34.69 | 2024 | Urgok2 |
| Kci USA, INC. | $32.37 | 2023 | Activ.A.C. Ion Progress |
| Solventum Corporation | $21.07 | 2024 | Activ.A.C. Ion Progress |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.63 | 2023 | |
| Janssen Pharmaceuticals, INC | $18.72 | 2023 | Invega Sustenna, Invega, Invega Trinza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Glass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.